In the last two decades, developing drug delivery systems to achieve controlled release and enable drug targeting to specific tumor sites emerged as an attractive option for enhancing therapeutic window of cytotoxic agents. Among the vehicles of delivery, nanoparticles, albumin microspheres, and liposomes have been explored. The use of liposomes as drug carriers for chemotherapeutic agent had been recently reviewed by Cattel et al. 1) Gregoriadis, in 1981, 2) initiated the use of liposomes for manipulating drug distribution to improve antitumor efficacy and reduce toxicity. However, the rapid recognition and removal of these conventional liposomes from circulation by the reticulo-endothelial system (RES) and difficulties in liposome penetration into the tumor interstitial fluid limited its use.
3)
The PEG-coated liposome (Stealth liposomes) was a major breakthrough in prolonging liposomal drug circulation time as they are not easily recognized and removed by the RES. 4) It has also been demonstrated that PEG liposomes can reach tumor tissue via high and leaky vasculature of tumor. Multidrug resistance (MDR) is a major obstacle to successful clinical cancer chemotherapy, including DOX. 6, 7) It has been demonstrated that P-glycoprotein (P-gp), encoded by MDR (ABC) genes, plays a key role in tumor resistance to cancer chemotherapy. P-gp serves as an ATP-dependent drug efflux pump which reduces intracellular drug accumulation in multidrug resistant cells. 8) Liposome formulation itself seemed to be able to overcome a certain degree of MDR probably by enhancing drug delivery into tumors. 9) However, for tumors exhibiting higher resistance levels, liposomes may not circumvent MDR significantly by themselves as demonstrated in a rat glioblastoma tumor model 10) and in murine MDR models. 11) Trials of chemosensitization and targeting of anticancer drugs are numerous. For example, co-administration of a Pgp inhibitor or P-gp specific antibody with anticancer drug to enhance intracellular anticancer drug accumulation such as verapamil, 12) cyclosporine A, or Valspodar (PSC833), 13 ) the specific P-gp blockers GF 120918, 14) LY335979, 15) and, a monoclonal antibody against P-gp, MRK-16 16) had been carried out. Development of immunoliposomes is another direction for tumor targeting therapy of a variety of anticancer drugs. 17) Verapamil (VER) is a calcium channel antagonist with of P-gp inhibitory action. Usually, the doses of VER used as a resistance modulator are much higher (2-6 mM) than those for antiarrhythmic indications (0.4-1.2 mM). [18] [19] [20] As such, VER cardiotoxicity is a great concern. 21) In addition, P-gp expression is also expressed in normal cells. This leads to the problem where selectivity of MDR modulation have to rely on physiological differences between healthy and tumor tissues.
Previous in vitro study has shown that a combination of free VER (2-10 mM) and liposome-encapsulated doxorubicin induced a synergistic effect in overcoming drug resistance in HL-60 cells. 22) We hypothesized that liposomal encapsulation of doxorubicin together with VER would be stable, and would demonstrate similar favorable cytotoxicity in MDR overexpressing tumor cell lines. If this were so, it would be an attractive strategy to develop this formulation further with the expectation that the liposomal less-cardiotoxic VER may be clinically relevant to reverse P-gp mediated drug efflux of DOX.
The objectives of the present study were, firstly, to incorporate DOX with VER into Stealth liposomes to formulate DOX antiresistant Stealth liposomes (DARSLs), and secondly, to investigate the in vitro cytotoxic effectiveness of DARSLs in DOX-resistant MES-SA/DX5 (human uterus sarcoma cell line) and DOX-resistant rat prostate cancer cell line (Mat-LyLu-B2, (MLLB2)) which expressed MDR gene. Cell Lines Mat-Ly-Lu-B2 (MLLB2) cell line was purchased from ATCC (U.S.A.). MLLB2 was developed from the MAT-Ly-Lu cell line. This cell line was tested by western-blot and showed to have high expression of P-gp at 170 KD.
MATERIALS AND METHODS

Materials
MES-SA (sensitive) and MES-SA/DX5 (resistant) cell lines were obtained from ATCC (U.S.A.). The MDR cell line MES-SA/DX5 was established from Parental MES-SA cells (human uterus sarcoma cell line) which were grown in the presence of increasing concentrations of DOX.
Liposome Preparations The different liposomes were prepared according to Haran et al. 23) DARSLs was prepared by incorporating both DOX and VER into Stealth liposomes, according to the following process. EPC (100 mmol), CHOL, PEG 2000 -DSPE (50 : 45 : 5 mol ratio) were dissolved in chloroform. The chloroform was evaporated to dryness under vacuum with a rotary evaporator (IFQ-85A), and the lipid film was hydrated with 10.0 ml of ammonium sulfate solution (150 mM) by sonication in water bath at 60°C for 30 min, and a suspension containing blank liposomes was obtained. The liposomes were then extruded five times through each polycarbonate membranes (Nucleopore, U.S.A.) of pore sizes 0.6, 0.4, 0.2 mm consecutively to make smaller size of liposomes. The resulting liposomes were dialyzed (MWCO 12000-14000; Servapor TM , Serva Germany) for 40 h at 4°C against 100 mM phosphate buffer (pH 7.4). Drug solutions of DOX, VER, or mixtures of DOX and VER at appropriate concentrations and blank liposome suspensions were mixed and incubated at 60°C for 30 min by occasional shaking, and the different formulations as well as DARSLs were obtained. Unencapsulated DOX and VER were removed by centrifugation through Sephadex-G50 mini columns.
Characterization of DARSLs Morphology and particle size of DARSLs were observed by Philips EM 400T electron microscopy and Zetasizer 3000HSA, respectively. The concentration of lipid associated with DARSLs was determined by methods established by Stewart. 24) Entrapped DOX and VER concentrations were measured by HPLC concurrently after disruption of the liposomes with methanol. In brief, liposomes disrupted with methanol were injected on to a HPLC C18 reverse phase column and DOX concentrations were determined with fluorescence at 580 nm and VER at UV 210 nm. The isocratic mobile phase consisted of 20 mM phosphate buffer (pH 4.0, 10% triethylamine) : acetonitrile : methanol (45 : 20 : 35, v/v) delivered at a rate of 1.0 ml/min. Leakage of Doxorubicin from Liposomes in Different Medium in Vitro DOX loading into liposomes at high concentrations using the ammonium sulfate gradient method is known to result in quenched fluorescence. Leakage of DOX from these liposomes can be easily measured using a fluorescence method. Briefly, DARSLs or LD were passed through a Sephadex G-50 column immediately prior to use to remove any free VER or DOX. One hundred microliters of liposomes was incubated at 37°C in 900 ml of various phosphate buffer solutions, human plasma, or cell culture medium (RPMI-1640) containing 10% fetal bovine serum (FBS) in 24-well plates at a final DOX concentration of 10 mg/ml (equal to 17.2 mM), and incubated at 37°C with using a shaker. Complete release of DOX was obtained by treating liposomes with 50 ml of 10% Triton X-100. At various time points (0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 h), the leakage percentage of DOX was calculated from fluorescence intensity of each well at selected time points relative to complete release. DOX leakage was determined by fluorescence detection at excitation and emission wavelengths of 485 nm and 580 nm, respectively.
MTT-Assay for the in Vitro Cytotoxicity The MTT assay was performed according to Hansen et al. 25) In brief, 5ϫ10 3 cells (MLLB2, MES-SA and MES-SA/DX5) were seeded in each well in a 96 well plate. Twenty-four hours later, fresh medium containing series concentration of various drug formulations, including free DOX (FD), liposomal DOX (LD), mixture of free DOX and free VER (FDFV), mixture of free DOX and liposomal VER (FDLV), mixture of liposomal DOX and free VER (LDFV), mixture of liposomal DOX and liposomal VER (LDLV), and DARSLs were added. Cells incubated in medium without any drug or liposomes were used as controls. After 72 h incubation, 20 ml MTT (5 mg/ml) was added, and the plates were incubated for an additional 4 h. Culture medium was removed, the formazan crystals were dissolved in 100 ml DMSO, and the absorbance value were read on a microplate reader (SPECTRAmax, Molecular Device Corp.) at the dual wavelengths of 570 nm and 650 nm.
Analysis of Intracellular DOX The inherent fluorescence of DOX (excitation 480 nm, emission 575 nm) was used to determine the association of DOX with MLLB2 cells, using flow cytometry. 26) MLLB2 cells were incubated with various formulations of DOX (FD, FDFV or DARSLs, 3.3 mM DOX and 5 mM VER) for 1, 4, 8, 24, 48, 72 h in incubator at 37°C. After incubation, cells were washed with cold PBS buffer and immediately run on an Epics Elite FCM (Coulter, U.S.A.). DOX molecular associated with cells was excited with an argon laser (488 nm) and the emitted fluorescence could be detected through 575 nm band pass filter. Files were collected of 20000 ungated events and were later analyzed using the WinWDI software (Ver2.8). If possible, washed cells were lysed and the released DOX was deter-mined by HPLC briefly described below.
HPLC Assay for Intracellular DOX 5ϫ10 5 MLLB2 cells were seeded in 6-well and grown for 24 h. Then various DOX formulations containing 3.3 mM DOX and 5 mM VER were added in medium and incubated with cells for 1, 2, 4, 8 and 24 h. At each time point, cells were trypsinized and washed 5 times with cold PBS buffer, then centrifuged and the pellets were stored in Ϫ20°C freezer. The HPLC assay was used to analyze intracellular DOX. Briefly, sample was extracted with chloroform/methanol (4/1, v/v), then injected onto a HPLC C18 reverse phase column and detected via DOX intrinsic fluorescence at 550 nm. The isocratic mobile phase consisted of buffer (1% ammonium hydroxide, adjusted to pH 4 by 98% formic acid) : acetonitrile (73 : 27, v/v) delivered at a rate of 1.0 ml/min. Daunorubicin was used as the internal standard.
Real-Time Intracellular Distribution of DARSLs Laser scanning confocal microscopy (LSCM), allowing the optical sectioning of the cells, represents a suitable tool for the fine intracellular localization of fluorescence substances. [27] [28] [29] MLLB2 cells were seeded for 24 h and realtime scanning was begun from the addition of FD, FDFV or DARSLs (DOX 3.3 mM, VER 5 mM) in cell culture medium at 37°C. Fluorescence images were taken with inverted Zeiss confocal laser scanning microscope (LSM510; Carl Zeiss, Jena, Germany) attached to a Zeiss Standard microscope using a Zeiss Plan-Apochromat 63ϫ/1.4 oil DIC immersion objective lens (Zeiss, Germany). Drug fluorescence was excited by the 560 nm laser line of an argon ion laser and was collected after passing through a long-pass dichroic filter with half-maximal cutoff at 540 nm and a barrier filter with a half-maximal cutoff at 550 nm. Cellular autofluorescence was negligible at the usual gain setting and was not subtracted. Optical sections of 1 mm were obtained. Photographs representing computer-enhanced images from confocal microscopy were allowed to be a qualitative estimation of intracellular distribution of DOX fluorescence.
Cell Cycle Analysis by Flow Cytometry Cytotoxicity of DOX on MLLB2 cells was evaluated using the DNA-binding dye propidium iodide. 26) MLLB2 cells (1ϫ10 6 /well) were incubated with fresh medium containing different formulations of DOX (FD, FDFV and DARSLs, 3.3 mM DOX and 5 mM VER) for 72 h in incubator at 37°C. After incubation, cells were trypsinized, and washed with PBS, fixed with 70% ethanol at 4°C overnight. Cells were stained with 0.3 ml of 50 mg/ml propidium iodide and 100 units/ml RNase. Samples were stored on ice in dark for 30 min prior to running on the flow cytometry. Files of 20000 ungated events were collected and analyzed by WinWDI software (Ver2.8). The position of the diploid peak was set on a linear fluorescence scale and appropriate markers were set to detect diploid, hypodiploid or apoptotic cell.
Statistical Analysis Statistical significance between two treatment pairs in this study was measured by Student's t-test, and statistically significance was set at p valueϽ0.05. Data were reported as meanϮstandard deviation (S.D.).
RESULTS
Characterization of Liposomes Different conditions
and weight ratios of drugs to lipid (blank liposomes) for encapsulation were investigated before selecting the optimum weight ratio of 1 : 0.11 : 10 (DOX : VER : lipid). The encapsulation efficiencies of DOX and VER into DARSLs were more than 90% and 70%, respectively. Morphology of DARSLs was shown in Fig. 1 and the average particle size of DARSLs obtained was 118.1Ϯ22.3 nm, similar as seen in blank liposomes and LD.
Leakage of DOX and VER from Liposomes The results of both liposomes, LD ( Fig. 2A) and DARSLs (Fig.  2B) , showed minimal leakage (Ͻ5%) of DOX from liposomes in PBS (pH 7.0 or pH 7.4), after 48 h incubation at 37°C. In cell culture medium containing 10% FBS, the DOX leakage from LD and DARSLs was Ͻ15% after 48 h incubation. In human plasma, the DOX leakage from DARSLs and LD was 35% and 25%, respectively, after 24 h incubation. The presence of VER in DARSLs increased DOX leakage (pϽ0.05) when compared to LD. Stability of VER in liposomes was also investigated. The results showed that the release of VER from DARSLs was similar to DOX in cell medium, less than 10% after 12 h incubation.
MTT Assay The IC 50 of MLLB2 as measured by MTT assay of the various formulation (Table 1) were as follows: DARSLs (0.079 mM)ϳLDLV (0.099 mM)ϽFDFV (0.147 mM) ϽFDLV (0.303 mM)ϽLDFV (0.96 mM)ϽLD (88.6 mM)Ͻ FD (140.87 mM). DARSLs was most cytotoxic. The IC 50 value of the DARSLs for MLLB2 cells was 13 fold (pϽ0.01) less than that for LDFV but was only about 2 fold less than FDFV. There was no significant difference between the formulation of LDLV and DARSLs but there was significant difference between the LDFV and FDLV (pϽ0.05).
IC 50 observed in the resistant MES-SA/DX5 cells were generally higher than that in the MLLB2 cells: DARSLs (0.13 mM)ϳLDLV (0.14 mM)ϳFDFV (0.13 mM)ϳFDLV (0.14 mM)ϽLDFV (0.21 mM)ϽLD (2.12 mM)ϳFD (2.30 mM). The IC 50 of free DOX on sensitive MES-SA cells was about 0.16 mM. The IC 50 of DARSLs for MES-SA/DX5 was about 18 fold (pϽ0.01) less than that for FD. The presence of VER whether free or encapsulated reversed DOX-resistance to produced IC 50 similar to that of FD in sensitive MES-SA cells. Stealth liposome encapsulating DOX (LD) alone was not enough to reverse the resistance of these two resistant 824 Vol. 28, No. 5 cell lines (MLLB2 and MES-SA/DX5). Accumulation of DOX in MLLB2 Cells Intracellular DOX fluorescence was shown in Fig. 3 . The intensity was as follows: DARSLsՅFDϽFDFV at 8h incubation, but after 24h incubation, DARSLs showed higher intensity than FD (pϽ0.01), but significant lower than FDFV (pϽ0.01). Intracellular uptake of DOX up to 24 h incubation was confirmed by cell lysis and HPLC determination of DOX.
Intracellular DOX Distribution Real-time uptake process of free DOX in cells on confocal microscopy (Fig.  4A) showed DOX fluorescence to be distributed exclusively in cytoplasm after incubation for 6 h in MLLB2 cells. DOX distribution for FDFV and DARSLs were similar but the whole process for DARSLs was much slower. DOX fluorescence was located in cytoplasm and also in nucleus within 0.5 h with FDFV (Fig. 4B) while similar distribution could only be seen for DARSLs at 6 h (Fig. 4C) . After 6 h, intracellular distribution of DOX continued to be similar for both FDFV and DARSLs.
Cell Cycle Analysis Figures 5a-d were typical photograms from 3 experiments. Figure 5a showed DNA content of untreated MLLB2 cells in cell cycle at G0/G1, S, and G2/M phase. The DNA content of cells treated with different DOX formulations were shown in Figs. 5b-d . The DNA profile of cells treated with FD remained similar to that of the untreated cells, namely mainly diploid (G1/G0), and a little of quadruploid (G2/M). In contrast, the DNA profiles of cells treated with FDFV and DARSLs showed that the G1/G0 phase cells were reduced with different extent (78% for FDFV, and 42% for DARSLs, respectively), corresponding to these results, the G2/M phase cells were increased by 290% and 125% respectively (Figs. 5c, d) . Although apoptotic phase was observed with both FDFV and DARSLs, the fractions were very small but similar.
DISCUSSION
This is the first report of an in vitro cytotoxic study on liposomes co-encapsulated with an anticancer drug DOX together with a multidrug resistant modulator VER.
Morphology and particle size of liposomes with DOX alone (LD) or with DOX and VER (DARSLs) as determined by transmission electron microscopy and light scattering scanning technology were similar. The mean diameter of unilamellar liposomes of 118Ϯ22.3 nm obtained is small enough to allow diffusion into malignant tissue via gaps pre- a) MLLB2 cells (5000/well) were incubated in complete RPMI-1640 medium with either free DOX (FD) or various formulations of DOX (refer to text for formulation codes) for 72 h at 37°C in an atmosphere of 95% humidity and 5% CO 2 . MTT assay was analysed by microplate reader at wavelengths 570 nm and 650 nm (nϭ3-6). b) Reversal efficiency was calculated from the ratio between the mean IC 50 values of other DOX formulations and Free DOX only. FD is free DOX; FDFV is free DOX with free VER; LD is liposomal DOX; LV is liposomal VER; LDFV is liposomal DOX with free VER and DARSLs is liposomal DOX with liposomal VER. sent in the highly permeable nascent tumor blood vessels. 30) The stability of liposomes is an important characteristic for clinical applicability of liposome formulation. For DARSLs, high stability was obtained with buffers but the addition of VER increased slightly the DOX leakage from liposomes only in the presence of plasma. However, the total leakage of DOX from DARSLs in plasma was about 20% of encapsulated drug within 12 h incubation. This should not be a problem if DARSLs is used in vivo as most of the liposomes/drug would have distributed into different tissues within 12 h and its therapeutic effect would not be affected.
The combination of VER and liposomal DOX has been shown to exhibit a synergistic effect in cells. 31) Liposomal DOX (Doxil ® ) improved clinical therapeutic index of DOX with reduced cardiotoxicity. 32) To investigate the cytotoxicity of DARSLs, we selected 2 cell lines (MLLB2 and MES-SA/DX5) which expresses P-glycoprotein. For both resistant cell lines, the significant finding was that Stealth liposome encapsulating DOX alone without VER was not enough to reverse resistance. DARSLs reversed DOX-resistance of MES-SA/DX5 and MLLB2 cells but the reversals were very different being 18 fold and 1783 fold respectively. In MLLB2 cells, IC 50 of encapsulated VER in DARSLs (0.079 mM) was the most effective, 13 fold lower than that for free VER LDFV (0.958 mM) ( Table 1) . For the MDR MES-SA/DX5, similar IC 50 were seen with all formulations with VER free or encapsulated. The pronounced differences in DARSLs effects between the cell lines could be attributed to MES-SA/DX5 being an unique MDR cell line with respect to pHdependent vesicular drug accumulation. 33) Thus, the MLLB2 cell line where DARSLs showed a much higher reversal was selected for other experiments in this study.
Although DARSLs was the most cytotoxic on MLLB2 cells, the intracellular DOX concentrations with this formulation were significantly lower when compared to FDFV for all time points, and only higher than FD after 24 h (Fig. 3) . Furthermore, the observation was unlikely to be due to quenched DOX fluorescence measurement as reported for intact intracellular liposomes loaded using ammonium sulfate gradient 34) because uptake of DOX into cells were confirmed by HPLC. The contradictory result of higher toxicity for DARSLs with lower intracellular concentration of DOX is difficult to explain. We attributed it to difference in its slow DOX and VER release and its distribution into the cells e.g. differences of DOX distribution between endosomes and lysosomes which possess different pH gradients in cells during uptake of liposomal drug preparations.
33) The interactions of the liposomes or high lipid content with released DOX and VER on the MLLB2 cells in the in-vitro system could be another possible factor.
The release of free VER from liposomes in the in vitro cell medium was slow. In addition, VER in liposomes seemed to show different effects. FDLV formulation was less cytotoxic than FDFV, but its combination with liposomal DOX (DARSLs/LDLV) was more cytotoxic ( Table 1 ). The higher content of liposomes or lipids in these latter preparations could have affected the mechanism of action of cytotoxicity. 35 ) DOX distribution (confocal microscopy (Fig. 4) ) to nuclei and cytoplasm for DARSLs in cells was much slower than FDFV perhaps due to slow release of VER.
Taken together, our results suggested that the high cytotoxicity of DARSLs formulation in MLLB2 may be the modification of the in vitro cytotoxic mechanism of this preparation. Evidence to support this can be seen in the cell cycle studies (Fig. 5) . Cytotoxicity as measured by MTT was higher for DARSLs but its apoptotic marker was not. The MTT assay measures cytotoxicity (IC 50 ) as long as the mitochondria is non-functional (cytostatic) and therefore not necessarily at the apoptotic state. Much can be speculated on DARSLs's high cytotoxicity in MLLB2 cells. For example, the effects of liposome encapsulation on cellular membrane lipids, protein structures and fluidity resulted in an increase susceptibility to the cytotoxicity of DOX. VER and/or liposome activating P-gp leading to modulation of caspase activation with initiation of cell death process. 37, 38) Although the primary mechanism of action of DOX is inhibition of topoisomerise-II enzyme function, 39) liposomes could have caused dilatation of the Golgi apparatus and changed the efflux of various proteins 40) or affected other subcellular targets to cause cytotoxicity. DARSLs might have affected the P53 gene to arrest the cells at the G1 phase before apoptosis.
41)
The cell cycle DNA markers showed that FDFV and DARSLs have very low apoptotic marker (Ͻ2%). It is therefore believed that DOX from DARSLs at a much lower concentration can arrest cells activity (cytotoxic) as measured by MTT assay.
In conclusion, this study has demonstrated the effective reversal of multidrug resistance in the two DOX-resistant cell lines especially MLLB2 cells by the novel formulation of Stealth liposomes co-encapsulating DOX with VER (DARSLs). The mechanism of cytotoxicity of DARSLs in MLLB2 cells in vitro system seemed to be different from LDFV, and needs further evaluation and elucidation. This in vitro difference in mechanism of action may not be observed in in vivo system because the pharmacokinetic handling of the formulation would be different. Investigations of DARSLs in vivo for its pharmacokinetics and potential in reversing MDR tumor in rats is showing promise of efficacy with reduced cardiotoxicity. 
